Thanks to DataBiologics for featuring my work in regenerative medicine! It's been rewarding to see how these innovations can improve patient outcomes and quality of life, and their commitment to tracking these outcomes is a big part of helping us drive better recoveries and stronger results for patients.
Perhaps due to recent changes to FDA leadership with the new administration, there seems to be renewed interest in birth products, such as cord blood, placental tissue and Wharton's jelly, and their potential as orthobiologic treatments. Let's dive in...